Mon, August 2, 2010
Fri, July 30, 2010
Thu, July 29, 2010
Wed, July 28, 2010
Tue, July 27, 2010
Mon, July 26, 2010
Fri, July 23, 2010
Thu, July 22, 2010
Wed, July 21, 2010
Tue, July 20, 2010
[ Tue, Jul 20th 2010 ] - Market Wire
00 AM EDT
Mon, July 19, 2010
Sun, July 18, 2010
Sat, July 17, 2010
Fri, July 16, 2010
Thu, July 15, 2010
Wed, July 14, 2010
Tue, July 13, 2010

Ligand to Report Second Quarter Results on August 5th


//health-fitness.news-articles.net/content/2010/ .. report-second-quarter-results-on-august-5th.html
Published in Health and Fitness on Thursday, July 22nd 2010 at 6:10 GMT by Market Wire   Print publication without navigation


SAN DIEGO--([ BUSINESS WIRE ])--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report second quarter 2010 financial results on Thursday, August 5, 2010. Liganda™s President and CEO, John L. Higgins and Vice President of Finance and CFO, John Sharp will host the conference call.

Second Quarter Earnings Call

What: Ligand Pharmaceuticals conference call to discuss financial results and provide general business updates.
When: Thursday, August 5, 2010
Time: 6:00 a.m. Pacific time (9:00 a.m. Eastern time)
Webcast:

Conference call and replay accessible at [ www.ligand.com ].

Conference Call: (877) 407-4019, passcode: Ligand
(201) 689-8337 outside the U.S.
Replay: (877) 660-6853, Account #: 361 passcode: 353874
(201) 612-7415 outside the U.S.

About Ligand Pharmaceuticals

Ligand discovers and develops new drugs that address critical unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, Alzheimer's, inflammatory diseases, anemia, COPD, asthma, rheumatoid arthritis and osteoporosis. Ligand's proprietary drug discovery and development programs are based on advanced cell-based assays, gene-expression tools, ultra-high throughput screening and one of the world's largest combinatorial chemical libraries. Ligand has strategic alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Merck, Pfizer, Roche, Bristol-Myers Squibb, and Cephalon and more than 30 programs are in various stages of development by its partners.


Publication Contributing Sources